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Research in Context 
Evidence before this study 
We searched PubMed and Medline with the terms “acute liver failure” and “fulminant hepatic 
failure” to identify studies and publications in addition to those familiar to the authors or cited by 
guidelines. We used no date restrictions. Reference lists in identified reports were also reviewed to 
further identify studies of relevance to this study. This included identification of 3 meta-analyses of 
prognostic criteria in acute liver failure (ALF), but the majority of studies reporting survival outcomes 
were case series from single centres with cohorts of limited size and open to reference bias. 
Available evidence suggests that survival of patients with paracetamol-induced ALF managed with 
medical care alone has progressively increased over time, and that existing criteria used to select 
candidates for emergency liver transplantation (ELT) may no longer be effective.  
Added value of this Study 
This study presents novel criteria for the assessment of prognosis in paracetamol-induced ALF, 
derived and validated in a very large multi-centre patient cohort. The models developed reflect the 
current outcomes of the illness and utilise readily available clinical variables and standardised 
definitions, with sequential assessment to assess changing prognosis over time. For the first time the 
models enable individualised and updated survival predictions to be made and address key practical 
issues in relation to clinical use.  
Implications of all the available evidence 
ELT may be life-saving in selected patients with paracetamol-induced ALF, however many of those 
transplanted using existing criteria may have survived with medical management alone. The use ELT 
for this indication requires comprehensive re-evaluation. 
  
Abstract 
Background 
Early, accurate prediction of survival is central to management of patients with paracetamol-induced 
acute liver failure (P-ALF) to identify those needing emergency liver transplantation (ELT). Current 
prognostic tools are confounded by recent improvements in outcome independent of ELT, and 
constrained by static binary outcome prediction. We developed a simple prognostic tool that 
reflected current outcomes, generating a dynamic updated estimation of risk of death. 
Methods 
1028 Patients with P-ALF managed at intensive care units in the United Kingdom (London, 
Birmingham, Edinburgh) and Denmark (Copenhagen) were studied. Prognostic models were 
developed, excluding transplanted patients, using Cox Proportional-Hazards in a derivation (n=350), 
and tested in initial (n=150) and recent external (n=412) validation datasets. Mortality was 
estimated in those patients who had ELT (n=116) Model discrimination was assessed using area 
under receiver operating characteristic curve (AUROC) and calibration by Root-Mean-Square Error 
(RMSE). Admission (Day 1 (D1)) variables age, Glasgow Coma Scale, arterial pH and lactate, 
creatinine, INR, and cardiovascular failure were used to derive an initial predictive model, with a 
second (D2) model including additional changes in INR and lactate. 
Findings  
Applied to the derivation set the AUROC for 30-day survival using the D1 model was 0·92 (95% 
confidence interval 0·88-0·96) and D2 0·93 (0·88-0·97). In the initial validation set AUROC was 0·89 
(0·84-0·95) and 0·90 (0·85-0·95) with RMSE 0·1642 and 0·0626 and in the external validation set, 
0·91 (0·87-0·94) and 0·91 (0·88-0·95) and 0·079 and 0·107. Applied to 116 patients who underwent 
ELT, median predicted 30-day survival was 51% (33-85). 
Interpretation 
We present the development and validation of novel high performance statistical models to support 
decision-making in patients with P-ALF. The models show very good discrimination and calibration, 
confirmed in independent datasets and suggest that many of those transplanted using existing 
criteria may have survived with medical management alone. The role and indications for ELT in P-ALF 
requires re-evaluation.  
Funding: Unrestricted Grant from Liver Research Foundation  
Background 
Acute liver failure (ALF) is a rare critical illness, and in many countries, including the United Kingdom, 
paracetamol-induced hepatotoxicity its most frequent cause 1,2. The illness may follow a rapidly 
progressive course with severe hepatic necrosis quickly followed by the development of 
encephalopathy, multiple extra-hepatic organ failures and death 3. However, the condition is one in 
which there is marked variation in clinical course. In some patients’ recovery with medical therapy 
alone may be possible despite severe multiple organ failure, whilst in others survival may be 
impossible without emergency liver transplantation (ELT) 4,5. The early and accurate evaluation of 
expected prognosis is key to effective management, to enable successful transplantation in the 
narrow window of opportunity for those who will benefit from it, and avoiding unnecessary surgery 
in those who will survive with medical therapy alone. Tools available for prognostic evaluation are 
available, but their limitations are increasingly apparent 6-8. 
Prognosis in paracetamol-induced ALF (P-ALF) is most commonly assessed using the Kings College 
Criteria (KCC). The criteria were derived from the analysis of patients managed in a single centre 
between 1973 and 1987 and have been in use to select transplant candidates for more than two 
decades6. Poor prognosis criteria include an arterial pH of <7.3 after volume resuscitation, or the 
combined findings of high grade encephalopathy, creatinine of more than 300 µMol/l and INR ≥6.5 
occurring within a narrow time frame 6. Early meta analysis of the KCCs diagnostic performance in P-
ALF suggested high specificity but more limited sensitivity; the introduction of arterial blood lactate 
concentration as a supplemental marker was proposed to address this issue 7-9. However, the 
increasing success of non-transplantation medical therapies alone is likely to have affected the 
performance of the KCC in patients with P-ALF as in the last three decades marked improvements in 
survival with medical care alone have occurred for many aetiologies of ALF, particularly those cases 
resulting from paracetamol-induced hepatotoxity3. These improvements in non-transplant outcomes 
have not been reflected in changes in recognised indications for ELT. 
Experience has also shown practical issues in the use of the KCC. They were intended for use in a 
transplant centre and not early after presentation in the emergency room where intravenous fluid 
resuscitation has not been undertaken and the effect of high blood levels of paracetamol may 
contribute to a reversible lactic acidosis 10,11. They perform less accurately in accidental or 
intentional staggered overdoses of the drug than after single time point deliberate ingestions, and 
be difficult to interpret as their component variables may be confounded by alteration by medical 
interventions 12. As they provide a binary outcome prediction rather than a continuum of risk, their 
application may also be difficult, and they do not address a key clinical dilemma in the waitlisted 
patient who shows signs of improvement – is it better to remove them from the list or to proceed 
with transplantation? 
In exploring the development of a novel model for the prediction of death without transplantation in 
patients with paracetamol-induced ALF, our study design sought to address the limitations of the 
present KCC. By studying more recent cohorts we hoped to reflect the current outcomes of the 
illness and develop a model utilising readily available clinical variables and standardised definitions, 
with sequential assessment to assess changing prognosis over time 13. The objective was to develop 
a decision support tool that was simple to use and gave a continuous and updated estimation of risk 
of death rather than a static binary outcome prediction. We hoped to avoid the reference bias that 
may complicate studies of prognosis in ALF by excluding those patients who underwent 
transplantation, and to assess reproducibility and transportability by the use of multiple validation 
cohorts.  
Patients and Methods 
Patients with severe paracetamol-induced hepatotoxicity managed at specialist liver transplantation 
intensive care units (ICU) in the United Kingdom and Denmark were studied. In all cases a history of 
drug ingestion and / or detectable blood paracetamol was present with the exclusion of other causes 
of acute liver injury. Other inclusion criteria included an INR of ≥ 1·5 and absence of a previous 
history and clinical / radiologic findings of liver disease. The primary derivation and initial internal 
validation test cohorts were derived from consecutive non-transplanted patients with severe 
paracetamol-induced hepatotoxicity admitted over the period 2000-2012 to the Liver Intensive 
Therapy Unit (LITU) at Kings College Hospital (KCH), London UK.  
External validation cohorts included 151 non-transplanted patients over the period 2011-13 from 
the Rikshopitalet liver unit in Copenhagen, Denmark, 90 patients from 2008-14 admitted to the 
Scottish Liver Transplant Unit at the Edinburgh Royal Infirmary, 72 patients from 2004-13 treated at 
the ICU of Queen Elizabeth Hospital, Birmingham UK and a further 99 patients treated at KCH LITU 
between 2012 and 2014. Features on admission of these cohorts are shown in table 2. Validating 
mortality in paracetamol-induced ALF is seldom an issue as almost without exception non-
transplanted death results during a single hospital admission, most commonly during the first ICU 
week , with rapid recovery seen in those who survive 14. 
A common approach to clinical management was applied in all units, with ELT considered in patients 
who fulfilled the standard KCC.  Standard medical care applied has been detailed elsewhere 3. In 
brief, patients developing encephalopathy grade ≥3 were intubated, sedated and mechanically 
ventilated. Guided restoration of circulating volume was commenced immediately on admission and 
utilized invasive hemodynamic monitoring. Coagulopathy was not supported unless active 
haemorrhage was present 15. Norepinephrine was the primary vasopressor used and dobutamine 
the primary ionotropic agent with adjunctive use of intravenous low dose hydrocortisone and 
vasopressin. Renal replacement therapy (RRT) utilised continuous veno-venous hemofiltration 
(CVVHF). Indications for its use including not only those standard for patients with acute kidney 
injury with anuria but also for relative oliguria, metabolic stabilization and control of acidosis and 
hyper-ammonaemia. Sedation utilized fentanyl and propofol infusions with rare use of paralysis. 
Treatment for intra-cranial pressure crises was with bolus intravenous mannitol, hypertonic saline 
and increased sedation using thiopentone in refractory cases. Intravenous N-acetyl Cysteine (NAC) 
was administered to all patients with an infusion of 100 mg/kg/24 hrs for a maximum of 5 days or 
until the INR was <2.  
Datasets and Statistical Methods 
The derivation and initial validation patient datasets were drawn from the LITU clinical database 
where demographic, physiologic and laboratory parameters are prospectively collected daily on all 
patients by specialist audit nurses. This included those required for the Sequential Organ Failure 
Assessment (SOFA) score and Acute Physiology and Chronic Health Evaluation (APACHE) scores (web 
appendix page 1). Fewer than 1% of cases had missing values.   
Standardised scores were utilised assessing level of consciousness and grade of encephalopathy 
using the Glasgow Coma Scale (GCS), and cardiovascular dysfunction by the SOFA cardiovascular 
component score (SOFA CVS; web appendix page 2), with a score of 3 or above taken to represent 
cardiovascular failure (SOFA CVS Failure) 3,16,17. GCS was assessed in patients who had not received 
sedative agents, and if used these was taken as the lowest score prior to administration, except if 
signs of intracranial hypertension were present 3,18. Survival time was from date of admission to date 
of death. Continuous variables are summarised as mean (standard deviation) or median 
(Interquartile range (IQR)) and categorical data as count (percentage). Student’s t-test, Mann-
Whitney U and Wilcoxon signed-rank tests were used to test differences in continuous variables 
where appropriate, and the Chi-square test used for proportions. Multiple survival analyses were 
undertaken using Cox Proportional-Hazards models to determine the prognostic and predictive 
value of demographic factors and clinical variables. All-cause mortality was the primary event 
studied and transplanted patients were excluded from model development and primary testing. 
Variable selection and model fitting were conducted through backward stepwise regression based 
on p-values. The model starts with a range of clinical variables of important prognostic value 
suggested by literature review, and then goes through extensive backward stepwise model/variable 
selection process. The final models consisted of variables most strongly associated with death in the 
multiple Cox proportional hazards regressions. The proportional-hazards assumption for each 
covariate was tested using the scaled Schoenfeld residuals. The proportionality test showed that all 
the covariates followed the proportional-hazards assumption (P>0.05).  
To develop and validate the predictive survival models, we divided the KCH dataset into derivation 
set (n=350) and initial validation set (n=150) with random case selection. Survival models using day 1 
and day 2 were first built from derivation dataset separately and then validated in the validation 
dataset. The performance and predictive accuracy of the models were assessed using receiver 
operating characteristic (ROC) analysis. The ROC curves and values were compared among different 
models and also between derivation and validation stages.  Model calibration was assessed 
comparing observed and predicted survival using Root-Mean-Square Error (RMSE) 19.  All tests were 
2-tailed, and p-value < 0·05 was considered statistically significant. ROC values with 95% CI for all the 
survival models and hazard ratios (HR) with 95% confidence Intervals (CI) for the chosen clinical 
variables were calculated. Statistical analyses were performed with statistical software R, version 
2·11·1 and SPSS version 22·0·0.  All data was fully deidentifed before exchange and analysis and its 
use was approved by the Research Ethics Committee of Kings College Hospital. 
Results 
Characteristics of the derivation and initial validation sets are shown in table 1.  
Derivation Set 
 Seventy-eight (22%) of 350 patients in the derivation set died during hospitalisation; median day of 
death was 9 (IQR 2-14) days after admission. Non-survivors were older and on admission had 
evidence of more severe liver dysfunction with higher INR and arterial lactate levels and worse 
extra-hepatic organ failure with more severe encephalopathy, cardiovascular and renal dysfunction 
(table 3). Of note, 49 of 106 (46%) patients with GCS ≤9 on D1 died as compared to 29 of 244 (12%) 
with GCS above this threshold (Relative Risk 3·9 (2·6-5·8), p<0.0001).     
After extensive model fitting and variable selection, admission (D1) variables of age, GCS,  arterial pH 
and lactate, creatinine, INR, and SOFA CVS failure were identified as best clinical predictors. Hazard 
ratios for these component variables on admission are shown in table 4 (a) and the predictive 
equation in supplemental materials 2. Based on D1 model, we explored a day 2 (D2) model with 
additional changes in all clinical variables between day 1 and day 2, and after backward stepwise 
variable selection found only changes in blood lactate and INR to be significantly associated with 
survival. A dynamic (D2) survival model was thus further developed based on clinical variables on 
day 1 plus changes in blood lactate level and INR between day 1 and 2 to reflect the changing 
patterns in these critical variables (table 4 (b), web appendix page 3).  Exploration of models using 
data up to 7 days after admission did not demonstrate significant improvements in model 
performance above the D2 model. 
When applied to the initial validation set, AUROC for prediction of death at 7, 15 and 30 days using 
the D1 model was 0·95 (95% Confidence interval 0·91-0·99), 0·94 (0·90-0·97) and 0·92 (0·88-0·96) 
respectively, and for the D2 model 0·96 (0·93-1·0), 0·95 (0·91-0·98) and 0·93 (0·88-0·97) (figure 1 
(a) and (b)). Assessment of calibration utilising RMSE in prediction of 30-day survival gave values of 
0·1123 and 0·1317 for the D1 and D2 models respectively. 
Initial Validation Set 
Thirty-five (23%) of the 150 patients in the initial validation set died during hospitalisation. Using the 
D1 model AUROC for the prediction of death at 7, 15 and 30 days was 0·93 (0·86-1·00), 0·91 (0·85-
0·96) and 0·89 (0·84-0·95), and with the D2 model 0·94 (0·88-1·0), 0·91 (0·86-0·96) and 0·90 (0·85-
0·95) (figure 2 (a), (b)). Assessment of calibration utilising RMSE in prediction of 30-day survival gave 
values of 0·1642 and 0·0626 for the D1 and D2 models respectively (figure 2, (c), (d)). Based on the 
proposed survival models, individual survival curves were calculated and updated during the first 2 
days of ICU admission (figure 3).   
External Validation Sets 
Characteristics of the four validation sets differed significantly from one another and from the 
primary cohorts. Median age of the Danish patients was higher and the Birmingham cohort had 
more severe acidosis and lactate and creatinine, more severe encephalopathy and higher mortality 
(table 2). Overall, D1 single component variables were missing in 19 of 412 cases (5%) and D2 
variables in 141 (34%). Where D2 INR and lactate variables were missing, values were categorised as 
showing no improvement.   
AUROC and RMSE for the individual validation sets are shown in table 5. In the combined external 
validation sets, AUROC for 30-day survival for the D1 and D2 models was 0·91 (0·87-0·94) and 0·91 
(0·88-0·95) and RMSE 0·079 and 0·107 respectively (Figure 4).  
Patients Transplanted 
During the study periods of the derivation and validation sets, a total of 116 patients underwent ELT; 
84 at KCH, 23 at Birmingham and 8 in Edinburgh. Comparison of admission variables of those 
patients who died with those transplanted showed significant differences, with the former being 
older and with higher arterial lactate levels, and lower GCS and INR values (web appendix page 4).  
Using the D1 model, median predicted 30-day survival for the transplanted cohort was 51% (95% CI 
33-85) and where severe HE (GCS≤9) was present (n=70) predicted survival was 36% (18-73). 
Discussion 
In this report, we present the development and validation of high performance statistical models to 
support decision making in the care of patients with P-ALF. The models proposed show very good 
discrimination and calibration, confirmed on application to multiple independent external validation 
datasets with patients with a range of illness severity, and show considerable promise as prognostic 
tools. We developed models both on (D1) and after (D2) admission as their combined use provides 
practical support for key clinical decisions not addressed by existing single time point prognostic 
criteria. In management of P-ALF the first two days are critically important for the selection of 
transplant candidates; early prediction is required and is directly clinically relevant 14. Experience has 
shown that the clinical condition of patients with P-ALF may change rapidly after admission and 
initial therapy – with improvement in some and deterioration in others. The two stage assessment of 
prognosis permits quantitation of this change, objectively reassessing prognosis in those patients 
who show signs of improvement. Assessment of test performance showed both models to have high 
discrimination but importantly calibration was improved in the D2 model.  This sequential approach, 
derivation from recent patient cohorts and the utilisation of novel prognostic important variables 
represent clear advances beyond the original KCC. 
There has been criticism within the statistical literature on the use of stepwise regression for model 
fitting relating to its biases and suboptimal results. However, we used stepwise regression for its 
simplicity and in conjunction with expert opinion to decide which variables to include in the model. 
Our predictive models were robustly trained and validated on both internal and external datasets, 
which resulted in excellent model performance. Nevertheless, there are alternatives to stepwise 
regression which include Partial Least Squares Regression (PLS) and Least Absolute Shrinkage and 
Selection Operator (LASSO). These alternatives can overcome some of the shortcomings of stepwise 
regression although they have their own limitations 20. We will explore these novel methods in 
future research to further enhance the performance of our predictive models. 
We chose to exclude those patients who underwent ELT from model derivation and initial validation. 
Valid criticism can be made both of the inclusion or exclusion of transplanted patients in this process  
and both have been utilised in the literature. Our principal concern was of risk of reference bias 
given the dramatic improvements in survival with medical management alone in patients with P-ALF, 
and the possibility that detail of transplantation practice varied between centres 3,5 .Whilst this 
approach could introduce changes in cohort composition, it is unlikely to have yielded a less ‘sick’ 
sample as in key respects those who later died were more severely ill. Interpretation of the 
predictions of a survival model derived in a non-transplanted population applied to one that was 
transplanted must be with caution. However this survival estimate is derived from the analysis of a 
population of patients with illness of the same cause, which cases that had a range of disease 
severity that will have included patients of similar acuity and with a model that utilises variables 
derived solely from the pre-transplant phase of illness.  
When applying the D1 model to the patients transplanted during the study period, the median 
predicted survival was just more than 50% but fell to 36% when only those with severe 
encephalopathy (HE) were considered. These observations reinforce the key prognostic importance 
of its development and that transplantation should not be considered in the absence of high grade 
HE. Importantly they also suggest that an appreciable proportion of those transplanted might have 
survived with medical management alone. These findings quantify the marked improvements in 
survival independent of liver transplantation that have occurred over time and suggest that its place 
as an intervention in P-ALF requires comprehensive re-evaluation 21 3.  
In considering the application of these models in a clinical setting, limitations to their potential 
practical use must be assessed. In other critical-illness scoring systems, use for individual patient 
outcome prediction has historically been with caution, as the primary purpose of most such scores 
was for group outcome assessment and quality assurance 22-24. However, there is clear precedent 
within Hepatology for the use of scores, including MELD, for individual decision making in relation to 
transplantation – and in the widely accepted use of the KCC and other poor prognosis criteria for 
selection of patients with ALF for emergency liver transplantation 24,25. 
We see these models as tools to quantify the risk of death and support expert clinical judgement and 
decision making; experience in other areas of acute and critical care medicine suggests that 
combining an objective prognosis measure with a physicians clinical estimate results in the most 
accurate assessment of actual prognosis 23,26,27. Further, the sequential assessment our models 
provide is likely to be of benefit as in critically ill patients with and without liver disease, trends in 
illness severity provide additional prognostic value over single static determinations 23,28-30. Rather 
than considering a single time point survival estimate, transplantation wait listing decisions might 
best be made from observations of the dynamic course of the illness. An obvious issue is that of the 
threshold of estimated survival that should trigger wait listing; a figure of 25% demonstrated in 
recent reports of early transplantation for acute alcoholic hepatitis provides a useful parallel 31. A 
website has been developed to use the new paracetamol prediction models in a form that is 
accessible, easy to use and whose output will provide real-time estimates of expected survival, 
whilst accumulating a further prospective confirmatory validation set. 
In developing these models we deliberately chose not to place any reliance upon the reported 
timing of drug ingestion in our patient selection and survival modelling. In practice, this information 
is often inconsistent or unavailable and in the case of overdoses staggered over days defining a 
specific time point of ingestion impossible. Even without reliance upon this information, the model 
functioned well. However, it is important to recognise that these patients were assessed in liver 
transplantation centres usually days after drug ingestion, with established and significant hepatic 
necrosis and after receiving initial resuscitative measures at their receiving hospitals prior to 
transfer. Use of the models to predict survival in patients soon after overdose or at early after first 
presentation has not been assessed.   
These models were primarily designed to identify those patients whose survival would be enhanced 
by ELT. However, identification as having a poor prognosis does not necessarily mean that survival 
will be improved by liver transplantation. The models are designed to predict survival without 
transplantation but not survival after surgery, where factors not considered in our model are of 
prognostic importance 32. In many cases contraindications to ELT may be present and here the 
models may rather serve to guide patients and family members in the expected outcome of illness. 
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 Table 1. Demographics, clinical and laboratory findings and outcome of Derivation and Initial 
Valdidation Cohorts.  
  Derivation  Validation  
n   350  150   
Age (years)   37 (27-48)   36 (26-47)   
Gender (F)   188 (54%)   94 (63%)   
Died (%)   78 (22%)   35 (23%)   
Day 1      
HE Grade ≥3   149 (43%)   64 (43%)   
Glasgow Coma Score   13 (8-15)   14 (8-15)   
CVS Failure (n (%))*  83 (24%)  35 (23%)  
Mean Arterial Pressure (mmHg)  74 (63-95)  70 (61-90)  
INR   4·0 (2·6-6·2)   3·8 (2·8-6·0)   
Bilirubin (µMol/l)   68 (44-97)   72 (44-104)   
AST (IU/l)   5776 (2601-9809)   5215 (2089-9315)   
Creatinine ((µMol/l)  162 (92-267)   172 (93-281)   
Arterial pH  7·40 (7·31-7·4)  7·40 (7·31-7·43)  
Arterial Lactate (mMol/l)  2·8 (1.9-4.5)   2·6 (1·8-4·9)   
Day 2      
INR  3.0 (2.1-4.6)  3.0 (2.2-4.9)  
Arterial Lactate (mMol/l)  2.0 (1.4-3.2)  2.1 (1.4-3.2)  
Note; Data is median (interquartile range) or n (%). INR; International Normalised Ratio, AST; 
Aspartate Transaminase, HE; Hepatic Encephalopathy. * Sequential Organ failure Assessment (SOFA) 
Cardiovascular score ≥3 
  
Table 3. Comparison of demographics and admission characteristics of surviving and non-surviving 
patients of the derivation dataset.  
 
  Died  Survived  
n   78  272  
Age (years)   46 (37-53)  35 (25-45)  
Gender (F)   43 (55%)  145 (53%)  
INR   5.3 (3.3-8.7)  3.7 (2.6-5.7)  
Bilirubin (µMol/l)   60 (40-97)  69 (46-97)  
AST (IU/l)   6539 (3221-9999)  5545 (2454-9498)  
Creatinine ((µMol/l)  204 (151-289)  141 (82-248)  
Arterial pH  7·26 (7·17-7·37)  7·40 (7·36-7·42)  
Arterial Lactate (mMol/l)  7·6 (4·2-12·8)  2·4 (1·6-3·5)  
HE Grade ≥3   59 (76%)  90 (33%)  
Glasgow Coma Score   7 (6-11)  15 (10-15)  
CVS Failure (n (%)*  51 (65%)  32 (12%)  
Mean Arterial Pressure  63 (54-71)  78 (66-99)  
 
Note; Data is median (interquartile range) or n (%). INR; International Normalised Ratio, AST; 
Aspartate Transaminase, HE; Hepatic Encephalopathy. * Sequential Organ failure Assessment (SOFA) 
Cardiovascular score ≥3 
  
Table 2. Demographics, admission (day 1) laboratory findings and outcome of external validation 
sets.  
 
 Copenhagen Edinburgh Birmingham Kings All 
      
n 
 
151 90 72 99 412 
Age (years)  52 (36-61) 35 (27-46) 40 (31-46) 39 (30-50) 42 (31-53) 
Gender (F)  93 (61%) 49 (54%) 39 (54%) 59 (59%) 240 (58%) 
INR  3·0 (2·2-4·3) 5·3 (3·9-7·2) 4·9 (3-7·1) 6·2 (3·8-9·7) 3·9 (2·7-6·0) 
Arterial pH  
 
7·42 (7·36-7·46) 7·41 (7·31-7·47) 7·29 (7·19-7·38) 7·40 (7·35-7·45) 7·40 (7·30-7·45) 
Creatinine (µMol/l) 82 (56-153) 119 (73-216) 186 (96-297) 146 (76-273) 118 (66-236) 
Arterial Lactate (mMol/l) 2·6 (1·7-4·9) 2·9 (1·8-5·2) 5·6 (3·9-10·9) 3·3 (2·3-7·3) 3·5 (2·1-7·1) 
Glasgow Coma Score  15 (8-15) 15 (14-15) 9 (9-10) 14 (9-15) 14 (9-15) 
CVS Failure* 
 
26 (17%) 17 (19%) 57 (79%) 59 (60%) 159 (39%) 
Died (%)  23 (15%) 13 (14%) 36 (50%) 27 (27%) 99 (24%) 
 
Note; Data is median (interquartile range) or n (%).  INR; International Normalised Ratio.  * 
Sequential Organ failure Assessment (SOFA) Cardiovascular score ≥3 
  
Table 4 (a). Clinical Predictors included in admission (D1) predictive model in the derivation dataset 
(n=350). 
  Hazard Ratio 95% CI  p 
      
Age (5yrs)  1·07 (0·97-1·18)  0·168 
Day 1      
CVS Failure*  2·41 (1·39-4·17)  0·002 
Glasgow Coma Score  0·90 (0·84-0·98)  0·009 
Arterial pH  0·06 (0·01-0·61)  0·018 
Log (Creatinine (per 10 units))                     1·74 (1·12-2·7)  0·013 
Log (INR)  1·53  (1·04—2·24)  0·029 
Sqrt (Arterial Lactate)  2·01  (1·53-2·63)  <0·001 
  
  
Table 4 (b). Clinical Predictors included in Dynamic (D2) predictive model in the derivation dataset 
(n=350). 
  Hazard Ratio 95% CI  p 
      
Age (5yrs)  1·07 (0·98-1·18)  0·146 
Day 1      
CVS Failure  3·14 (1·8-5·49)  <0·001 
Glasgow Coma Score  0·90 (0·83-0·97)  0·005 
Arterial pH  0·09 (0·01-0·95)  0·045 
Log (Creatinine(per 10 units))                     1·70 (1·08-2·67)  0·022 
Log (INR)  1·97 (1·33—2·91)  <0·001 
Sqrt (Arterial Lactate)  2·01  (1·53-2·63)  <0·001 
Day 2      
Lower Arterial Lactate   0·31  (0·13-0·69)  0·0045 
Lower INR  0·54  (0·29-0·99)  0·046 
 
Note * Sequential Organ failure Assessment (SOFA) Cardiovascular score ≥3. Sqrt;  Square root.  
 
  
Table 5. Diagnostic test performance of D1 and D2 models for predicting 30-day survival applied to 
individual and combined external validation sets. 
  D1 Model    D2 Model     
         
Set n AUROC (95% CI) RMSE  AUROC 95% CI RMSE 
         
Copenhagen 151 0·93 (0·88-0·98) 0·140  0·94 (0·87-1·00) 0·208 
         
Edinburgh 90 0·88 (0·79-0·96) 0·281  0·89 (0·81-0·97) 0·239 
         
Birmingham 72 0·84 (0·74-0·94) 0·053  0·83 (0·73-0·93) 0·111 
         
Kings 99 0·92 (0·85-0·99) 0·117  0·93 (0·86-0·99) 0·185 
         
Combined 412 0·91 (0·87-0·94) 0·079  0·91 (0·88-0·95) 0·107 
 
Note: AUROC; Area Under Receiver Operating Characteristic Curve, RMSE; Root-Mean-Square Error. 
 
Figure 1.  Area under receiver operating characteristic curve (AUROC) for Kings College Hospital 
(KCH) Datasets. 
(a) D1 Model KCH Derivation Set (n=350). 
 
 
(b) D2 Model KCH Derivation Set (n=350). 
 
   
Figure 2.  Discrimination and Calibration of D1 and D2 models in KCH Validation set. 
(a) AUROC for D1 Model (n=150). 
 
 (b) AUROC for D2 Model (n=150). 
 
 
 
 (c) Calibration curve for D1 Model (n=150) 
 
(d) Calibration curve for D2 Model (n=150) 
 
 
 
 
  
Figure 3. Predicted Survival curves by D1 and D2 models for individual patients from KCH derivation 
set. 
(a) Patient died at day 23. 
 
(b) Patient survived to hospital discharge. 
 
Note; Hashed lines represent 95% confidence intervals for survival estimate.  
  
Figure 4. Discrimination and Calibration of D1 and D2 models in combined external validation sets 
(n=412).  
(a) Area under receiver operating characteristic curve (AUROC) for D1 Model  
 
 
(b) Area under receiver operating characteristic curve (AUROC) for D2 Model  
 

(c) Calibration Curve for D1 model  
 
(c) Calibration Curve for D2 model 
 
 
 
  
Supplemental Materials 1. 
Variables assessed in predictive model derivation: 
Age 
Gender 
Heart rate 
Mean Arterial Pressure 
Systolic Blood Pressure 
Diastolic Blood Pressure 
SOFA Cardiovascular Failure 
Respiratory rate 
PaO2/FiO2 ratio 
PaCO2 
Arterial pH 
Arterial [HCO3] 
Arterial [lactate] 
Blood concentrations: 
Sodium 
Potassium 
Creatinine 
Urea 
Leucocyte count 
Platelet count 
INR 
Bilirubin 
Aspartate Transaminase 
Albumin 
Glucose 
Glasgow Coma Scale 
Urine Output 
  
 Supplemental Materials 2. 
Predictive Equations for D1 and D2 Models 
Predictive equation for D1 model: 
Survival function (integration of hazard function over time 0 to t) is used to calculate the survival probability 
S(t) for any case at time t: 
Based on the estimation results (Hazard ratios) from the training dataset, we were able to calculate the survival 
probability for any patient at time t: 
𝑆(𝑡) = 𝑆0(𝑡)
𝐾 
K = ePI =exp⁡(𝑏𝑎𝑔𝑒 ∗ 𝑎𝑔𝑒 + 𝑏𝑐𝑎𝑟𝑑𝑖𝑜 ∗ 𝐶𝑎𝑟𝑑𝑖𝑜 + 𝑏𝐺𝐶𝑆 ∗ 𝐺𝐶𝑆 + 𝑏𝑝𝐻 ∗ 𝑝𝐻 + 𝑏𝑐𝑟𝑒𝑎𝑡𝑖𝑛 ∗ log(𝑐𝑟𝑒𝑎𝑡𝑖𝑛) + 𝑏𝐼𝑁𝑅
∗ log(𝐼𝑁𝑅)+𝑏𝑙𝑎𝑐𝑡𝑎𝑡𝑒 ∗ √𝑙𝑎𝑐𝑡𝑎𝑡𝑒
2
) = 1.07𝑎𝑔𝑒 + 2.41𝑐𝑎𝑟𝑑𝑖𝑜 + 0.90𝐺𝐶𝑆 + 0.06𝑝𝐻
+ 1.74log⁡(𝑐𝑟𝑒𝑎𝑡𝑖𝑛) + 1.53log⁡(𝐼𝑁𝑅) + 2.01 √𝑙𝑎𝑐𝑡𝑎𝑡𝑒
2
 
 
𝑆0(𝑡) can be estimated through the baseline cumulative hazard H0(t) and need help of statistical software. 
 
Predictive equation for D2 model: 
Based on the estimation results (Hazard ratios) from the training dataset, we were able to calculate the survival 
probability for any patient at time t: 
 
𝑆(𝑡) = 𝑆0(𝑡)
𝐾 
K = ePI =exp⁡(𝑏𝑎𝑔𝑒 ∗ 𝑎𝑔𝑒 + 𝑏𝑐𝑎𝑟𝑑𝑖𝑜 ∗ 𝐶𝑎𝑟𝑑𝑖𝑜 + 𝑏𝐺𝐶𝑆 ∗ 𝐺𝐶𝑆 + 𝑏𝑝𝐻 ∗ 𝑝𝐻 + 𝑏𝑐𝑟𝑒𝑎𝑡𝑖𝑛 ∗ log(𝑐𝑟𝑒𝑎𝑡𝑖𝑛) + 𝑏𝐼𝑁𝑅
∗ log(𝐼𝑁𝑅)+𝑏𝑙𝑎𝑐𝑡𝑎𝑡𝑒 ∗ √𝑙𝑎𝑐𝑡𝑎𝑡𝑒
2
+ 𝑏𝑑𝑦𝑛𝑎𝑚𝑖𝑐⁡𝑙𝑎𝑐𝑡𝑎𝑡𝑒 ∗ (𝑑𝑦𝑛𝑎𝑚𝑖𝑐⁡𝑙𝑎𝑐𝑡𝑎𝑡𝑒) + 𝑏𝑑𝑦𝑛𝑎𝑚𝑖𝑐⁡𝐼𝑁𝑅
∗ (𝑑𝑦𝑛𝑎𝑚𝑖𝑐⁡𝐼𝑁𝑅)) ⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡= 1.07𝑎𝑔𝑒 + 3.14𝑐𝑎𝑟𝑑𝑖𝑜 + 0.90𝐺𝐶𝑆 + 0.09𝑝𝐻
+ 1.70log⁡(𝑐𝑟𝑒𝑎𝑡𝑖𝑛) + 1.97log⁡(𝐼𝑁𝑅) + 2.01 √𝑙𝑎𝑐𝑡𝑎𝑡𝑒
2
+ 0.31(𝑑𝑦𝑎𝑚𝑖𝑐⁡𝑙𝑎𝑐𝑡𝑎𝑡𝑒) + 0.54(𝑑𝑦𝑛𝑎𝑚𝑖𝑐⁡𝐼𝑁𝑅) 
 
𝑆0(𝑡) can be estimated through the baseline cumulative hazard H0(t) and need help of statistical software. 
 
 
  
Supplementary materials 3.  
Comparison of demographics and admission laboratory findings of patients who died or underwent 
transplantation.  
 
  Died  Transplanted p 
n  185  116  
Age (years)   44 (35-54)  33 (24-40) <0·001 
Gender (F)   104 (56%)  75 (65%) 0·15 
INR   5·0 (3·3-8·7)  6·9 (4·4-10) 0·003 
Arterial pH   7·27 (7·15-7·38)  7·28 (7·20-7·38) 0·39 
Glasgow Coma Score  8 (6-10)  9 (7-12) 0·005 
Creatinine (µMol/l)  200 (128-282)  197 (129-298) 0·96 
Arterial Lactate (mMol/l)  8·1 (4·3-12·7)  5·9 (4-9·7) 0·01 
CVS Failure  151 (82%)  89 (77%) 0·30 
 
Note; INR; International Normalised Ratio.  Patients transplanted are 16%, 24% and 8% of the patient samples 
from Kings, Birmingham and Edinburgh cohorts  respectively. 
  
Supplementary Materials 4. 
The Sequential Organ failure Assessment (SOFA) Cardiovascular score 
    SOFA  Score 
No hypotension    0 
Mean Arterial Pressure <70mmHg    1 
Dopamine ≤5 or any dose Dobutamine    2 
Dopamine ≥5 or Epineprine ≤0.1 or Norepinephrine ≤0.1    3 
Dopamine ≥15 or Epineprine >0.1 or Norepinephrine >0.1    4 
 
Note: vasopressor drug doses are in µg/kg/min. 
 
Source: reference 16. 
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